{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-058866","form_type":"8-K/A","ticker":"GRDX","cik":"0001604191","company_name":"GridAI Technologies Corp.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.183573+00:00","generated_at":"2026-06-02T10:18:21.474935+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmunogenX reports net loss of $8.86M in 2023; auditor cites going concern doubts","bullets":["Net loss for 2023 was $8.86M, compared to $3.62M in 2022 and $1.66M in 2021.","Total assets of $4.1M vs. total liabilities of $18.33M as of Dec 31, 2023, resulting in stockholders' deficit of $14.23M.","Cash and cash equivalents only $251k as of Dec 31, 2023; auditor expressed substantial doubt about going concern.","Pre-revenue clinical-stage biotherapeutics company focused on celiac disease treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-058866","json":"https://secwatch.observer/filing/0001104659-24-058866.json","markdown":"https://secwatch.observer/filing/0001104659-24-058866.md","text":"https://secwatch.observer/filing/0001104659-24-058866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924058866/0001104659-24-058866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924058866/tm2413822d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:18:21.474935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}